Company intelligence / Profile preview
Centaurus Biopharma Co., Ltd.
Chifeng City, Inner Mongolia, Chinapmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Centaurus Biopharma has a diversified pipeline with a lead asset—Conteltinib—in Phase III trials for non-small cell lung cancer and pancreatic cancer. Other assets are in preclinical development targeting metabolic diseases and hematological malignancies. The company also offers CDMO services focused on chemical medicine innovation.[9][3]
- Therapeutic areas
- OncologyEndocrinologyImmunology
- Modalities
- Small molecules[1][2][9]
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Jiangsu Chia Tai TianqingLianyungang Ruzhong—collaborated on DPP-IV inhibitors patenting activity[5]
Beyond the preview
Go deeper on Centaurus Biopharma Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Centaurus Biopharma Co., Ltd..